| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/JVI.02084-16 |
| P8608 | Fatcat ID | release_loq6vylunngivhaodiowrlw2xm |
| P932 | PMC publication ID | 5286885 |
| P698 | PubMed publication ID | 27928016 |
| P50 | author | Roberto F Speck | Q60061521 |
| Mary-Aude Rochat | Q63969139 | ||
| P2093 | author name string | E Schlaepfer | |
| P2860 | cites work | Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection | Q21142645 |
| Evidence of LAT as a dual substrate for Lck and Syk in T lymphocytes | Q24300891 | ||
| The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes | Q24302212 | ||
| CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation | Q24310493 | ||
| The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter | Q24336893 | ||
| Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat | Q24537275 | ||
| Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue | Q24562082 | ||
| Targeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency | Q27026631 | ||
| Transcriptional Activation of Inflammatory Genes: Mechanistic Insight into Selectivity and Diversity | Q27026790 | ||
| The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors | Q27860900 | ||
| Depletion of latent HIV-1 infection in vivo: a proof-of-concept study | Q28111910 | ||
| Characterization of human inducible costimulator ligand expression and function | Q28142816 | ||
| ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells | Q28220104 | ||
| Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy | Q77890124 | ||
| Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking | Q79912711 | ||
| Differential ability of surface and endosomal TLRs to induce CD8 T cell responses in vivo | Q37728326 | ||
| Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses | Q38131901 | ||
| HIV-1 replication and latency are regulated by translational control of cyclin T1 | Q38273477 | ||
| Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells? | Q38527822 | ||
| Effects of prostratin on Cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cells | Q38557763 | ||
| Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal. | Q38830989 | ||
| Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial | Q38958099 | ||
| Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells | Q38958686 | ||
| Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir | Q39276828 | ||
| Seminal reservoirs during an HIV type 1 eradication trial | Q39312141 | ||
| TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-α. | Q39585002 | ||
| Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction | Q39694550 | ||
| Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction | Q39712159 | ||
| Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. | Q40155815 | ||
| Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy | Q28253761 | ||
| CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21 | Q28307312 | ||
| Epigenetic regulation of HIV-1 latency by cytosine methylation | Q28475636 | ||
| An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients | Q28538015 | ||
| The tyrosine kinase Syk differentially regulates Toll-like receptor signaling downstream of the adaptor molecules TRAF6 and TRAF3 | Q28590988 | ||
| Interleukin-12 and the regulation of innate resistance and adaptive immunity | Q29614602 | ||
| Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation | Q29615580 | ||
| Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy | Q29615992 | ||
| Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy | Q29615993 | ||
| Recovery of replication-competent HIV despite prolonged suppression of plasma viremia | Q29615995 | ||
| Functions of site-specific histone acetylation and deacetylation | Q29617894 | ||
| An inducible transcription factor activates expression of human immunodeficiency virus in T cells | Q29618434 | ||
| Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection | Q29619738 | ||
| Multiplexed particle-based flow cytometric assays | Q30925110 | ||
| Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission | Q31930812 | ||
| Anti-HIV activity mediated by natural killer and CD8+ cells after toll-like receptor 7/8 triggering | Q33330287 | ||
| Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection | Q33476165 | ||
| Contrasting roles for TLR ligands in HIV-1 pathogenesis | Q33700312 | ||
| Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape | Q33843371 | ||
| Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. | Q34057748 | ||
| Triggering TLR2, -3, -4, -5, and -8 reinforces the restrictive nature of M1- and M2-polarized macrophages to HIV. | Q34059582 | ||
| Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice | Q34180174 | ||
| Cell line-dependent variability in HIV activation employing DNMT inhibitors | Q34243934 | ||
| Molecular Characterization, Reactivation, and Depletion of Latent HIV | Q34263657 | ||
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy | Q34290545 | ||
| Evidence of dysregulation of dendritic cells in primary HIV infection | Q34310896 | ||
| Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it. | Q34312631 | ||
| The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit | Q34544409 | ||
| The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells | Q34629141 | ||
| Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies | Q34632118 | ||
| Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytes | Q34649701 | ||
| Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients | Q34700900 | ||
| Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling | Q34980925 | ||
| HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. | Q34985945 | ||
| Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of normal histone acetylation status upon removal of activators and repressors | Q35005811 | ||
| The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation | Q35072999 | ||
| T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway | Q35113716 | ||
| Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. | Q35168379 | ||
| Screening for noise in gene expression identifies drug synergies | Q35182580 | ||
| Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. | Q35192959 | ||
| Reactivation of latent HIV-1 by new semi-synthetic ingenol esters | Q35252396 | ||
| Direct Toll-Like Receptor 8 signaling increases the functional avidity of human CD8+ T lymphocytes generated for adoptive T cell therapy strategies | Q35285757 | ||
| Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations | Q35521811 | ||
| Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. | Q35720063 | ||
| Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells | Q35819184 | ||
| Regulation of cyclin T1 and HIV-1 Replication by microRNAs in resting CD4+ T lymphocytes. | Q35826285 | ||
| Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. | Q35845347 | ||
| Histone/protein deacetylases and T-cell immune responses | Q35849307 | ||
| Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism | Q35877276 | ||
| Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study | Q36053935 | ||
| CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. | Q36077348 | ||
| Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat | Q36086345 | ||
| Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection | Q36225040 | ||
| PKC phosphorylates HEXIM1 and regulates P-TEFb activity. | Q36305691 | ||
| Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation | Q36409885 | ||
| The pivotal role of TBK1 in inflammatory responses mediated by macrophages | Q36469148 | ||
| The SYK tyrosine kinase: a crucial player in diverse biological functions | Q36662082 | ||
| Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling | Q36673501 | ||
| HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression | Q36781531 | ||
| Interleukin-7 promotes HIV persistence during antiretroviral therapy | Q36873277 | ||
| Toll-like receptors' two-edged sword: when immunity meets apoptosis. | Q37011869 | ||
| Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo | Q37031659 | ||
| Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study | Q37115594 | ||
| Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells | Q37139993 | ||
| Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memory T-cell fates | Q37209054 | ||
| IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection | Q37262403 | ||
| Reactivation of latent HIV-1 in central memory CD4⁺ T cells through TLR-1/2 stimulation | Q37305160 | ||
| Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. | Q37410726 | ||
| Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents. | Q37438640 | ||
| Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). | Q37684283 | ||
| TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. | Q40313202 | ||
| Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). | Q41141994 | ||
| The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection | Q41454651 | ||
| Differential activation-dependent regulation of integrin function in cultured human T-leukemic cell lines | Q41487715 | ||
| An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation. | Q41657915 | ||
| Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity | Q41843310 | ||
| Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. | Q41880147 | ||
| Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells. | Q42052356 | ||
| NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation | Q42128724 | ||
| p21 regulates the HIV-1 restriction factor SAMHD1. | Q42354536 | ||
| Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex | Q43265788 | ||
| Prostratin antagonizes HIV latency by activating NF-kappaB. | Q43551279 | ||
| Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. | Q43792135 | ||
| Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). | Q44072577 | ||
| Deciphering the transcriptional histone acetylation code for a human gene | Q44206986 | ||
| TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection | Q44308127 | ||
| Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania | Q44920559 | ||
| Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents | Q44928571 | ||
| TNF activates Syk protein tyrosine kinase leading to TNF-induced MAPK activation, NF-kappaB activation, and apoptosis | Q44968896 | ||
| Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques | Q45394653 | ||
| Differential regulation of virus-specific T-cell effector functions following activation by peptide or innate cytokines | Q45568650 | ||
| IL-7-dependent STAT-5 activation and CD8+ T cell proliferation are impaired in HIV infection. | Q46763048 | ||
| Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10. | Q47871390 | ||
| Signal 3 requirement for memory CD8+ T-cell activation is determined by the infectious pathogen. | Q50996907 | ||
| The protein kinase C agonist prostratin induces differentiation of human myeloid leukemia cells and enhances cellular differentiation by chemotherapeutic agents. | Q51030525 | ||
| Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. | Q52007779 | ||
| OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. | Q52019286 | ||
| Immune complexes and late complement proteins trigger activation of Syk tyrosine kinase in human CD4(+) T cells. | Q54537006 | ||
| HIV: Shock and kill. | Q55056512 | ||
| Re-emergence of HIV after stopping therapy | Q59060012 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | toll-like receptor | Q408004 |
| P577 | publication date | 2017-01-31 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV | |
| P478 | volume | 91 |
| Q90594756 | Barriers for HIV Cure: The Latent Reservoir |
| Q99406975 | Block and Lock HIV Cure Strategies to Control the Latent Reservoir |
| Q89620873 | Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs |
| Q52816327 | Novel Latency Reversal Agents for HIV-1 Cure. |
| Q63407933 | STING agonists activate latently infected cells and enhance SIV-specific responses ex vivo in naturally SIV controlled cynomolgus macaques |
| Q92527135 | Sensing of HIV-1 by TLR8 activates human T cells and reverses latency |
| Q92300043 | Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs |
| Q52431127 | Tackling HIV Persistence: Pharmacological versus CRISPR-Based Shock Strategies. |
| Q92097620 | Why and where an HIV cure is needed and how it might be achieved |
Search more.